Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

作者：Banna Giuseppe Luigi^*; Di Maio Massimo; Follador Alessandro; Collova Elena; Menis Jessica; Novello Silvia; Bria Emilio

来源：Lung Cancer, 2011, 73(1): 78-88.

DOI：10.1016/j.lungcan.2010.10.020

• Adjuvant chemotherapy
• Non-small cell lung cancer
• Postoperative radiotherapy
• Survey

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (<= 1). Post-operative radiotherapy (RT) is optional for pN2 tumours.
Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail.
Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians.
Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

• 出版日期2011-7